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Esophageal atresia (OA) represents one of the commonest and most severe develop-
mental disorders of the foregut, the most proximal segment of the gastrointestinal (GI) 
tract (esophagus and stomach) in embryological terms. Of intrigue is the common origin 
from this foregut of two very diverse functional entities, the digestive and respiratory 
systems. OA appears to result from incomplete separation of the ventral and dorsal parts 
of the foregut during development, resulting in disruption of esophageal anatomy and 
frequent association with tracheo-oesophageal fistula. Not surprisingly, and likely inher-
ent to OA, are associated abnormalities in components of the enteric neuromusculature 
and ultimately loss of esophageal functional integrity. An appreciation of such develop-
mental processes and associated defects has not only enhanced our understanding 
of the etiopathogenesis underlying such devastating defects but also highlighted the 
potential of novel corrective therapies. There has been considerable progress in the 
identification and propagation of neural crest stem cells from the GI tract itself or derived 
from pluripotent cells. Such cells have been successfully transplanted into models of 
enteric neuropathy confirming their ability to functionally integrate and replenish missing 
or defective enteric nerves. Combinatorial approaches in tissue engineering hold signifi-
cant promise for the generation of organ-specific scaffolds such as the esophagus with 
current initiatives directed toward their cellularization to facilitate optimal function. This 
chapter outlines the most current understanding of the molecular embryology underlying 
foregut development and OA, and also explores the promise of regenerative medicine.
Keywords: esophageal atresia, tracheo-esophageal fistula, foregut development, stem cell, tissue engineering, 
enteric nervous system
iNTRODUCTiON
OA affects approximately 1 in 3,500 live births (1). Surgical correction aims at reconstituting gut 
continuity and disrupting the connection between the digestive and respiratory systems but despite 
considerable surgical expertise, including the introduction of minimally invasive approaches, the 
prognosis remains guarded and quality of life throughout childhood and adolescence poor. Affected 
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children and adults continue to suffer from severe gastroe-
sophageal reflux (GER), esophagitis, dysphagia, and esophageal 
dysmotility as well as poor weight gain together with chronic 
respiratory infections, tracheomalacia, and decreased exercise 
tolerance (2, 3). Although definitive surgery is carried out early 
in life, children with OA often require further interventions such 
as esophageal dilatations.
Surgically, OA is typically classified in two main groups 
accord ing to the distance of separation between the two esopha-
geal pouches: long gap OA and non-long gap OA. The most 
used definition of long gap OA is a gap greater than two to four 
vertebral bodies or 4–6 cm in length, although others have defined 
it as the inability of joining the esophagus at the first surgery with 
the result that there has been no unanimous definition for the 
two groups (4). In the current issue, the International Network of 
Esophageal Atresia has proposed that any OA that has no intra-
abdominal air should be considered as long-gap (see the article by 
Van Der Zee et al.).
While other classifications are available and discussed in other 
articles of this special edition, the authors believe that distinguish-
ing long gap OA from other forms is therapeutically important. 
In this group of patients, repair can present a significant surgical 
challenge and an esophageal replacement is often used. This can 
include gastric transposition (often called “gastric pull-up”) (5), 
colonic (6), or jejunal interposition (7). Such interventions are 
generally reliant on the position and length of the remaining 
native esophagus. During gastric pull-up procedures, the entire 
stomach including its vascular supply is moved into the mediastinum 
and a pyloroplasty is usually performed in an attempt to avoid 
delayed gastric emptying (8). An esophageal substitute can also 
be created from the larger curvature of the stomach, without mov-
ing the stomach itself [gastric tube esophagoplasty (9)]. In other 
cases, either jejunum or colon is used as substitute, with sections 
of these organs moved together with their own vasculature (6–8). 
More recently, closure of the gap by mechanical lengthening via 
external traction has been attempted by several surgeons (10–12), 
with Khan et al. reporting preservation, in terms of thickness, of 
the mural layers of the esophagus after this treatment (13).
Despite these efforts a definitive therapy for OA has yet to be 
developed. Such efforts have been halted somewhat by a failure 
in determining the precise etiopathogenesis of OA in human 
patients. Even with advances in genetic diagnostics, the genet-
ics of OA represents a challenge, as the condition is frequently 
associated with malformations in other organs, especially con-
genital defects of the heart and of other endodermal organs. For 
instance, VACTERL syndrome is characterized by the involve-
ment of defects in at least three body systems from the vertebral, 
anorectal, cardiovascular, tracheal, esophageal, renal, and limb 
systems. Tracheo-esophageal fistula (TOF) has been reported 
to be variably associated with this syndrome in between 50 and 
80% of cases (14–16). There is, however, emerging evidence of an 
important role for genetic factors in the molecular specification 
of foregut development. Significant evidence has been garnered 
from multiple transgenic animal models, which are beginning 
to shed light on possible dysfunctional mechanisms resulting 
in OA ±  associated TOF, which may have translational conse-
quences for clinical diagnostics in human OA.
GROSS DeveLOPMeNT OF THe 
FOReGUT: MODeLS FOR THe 
PATHOGeNeSiS OF OA/TOF
The gastrointestinal (GI) tract is a complex physiological system 
comprising the hollow organs of the digestive system (pharynx, 
esophagus, stomach, intestine, and colon), usually termed the 
“gut” and the GI tract derivatives (thyroid, thymus, parathyroid, 
lungs, liver, and pancreas). Throughout the GI tract, each region 
exists as a sophisticated multi-layered system consisting of a 
mucosal layer, neural plexuses, and a number of muscle layers. 
Developmentally, all three germ layers participate in the forma-
tion of the gut. The endoderm and mesoderm form the epithelial 
layer and muscle layers, respectively, with the ectoderm forming 
the various neural plexuses present throughout the GI tract 
termed “the enteric nervous system.” Initially, the embryonic gut 
develops as a result of cephalocaudal and lateral embryo folding 
and incorporation of the endoderm-lined yolk sac. This leads to 
the formation of two blind-ending endodermal invaginations at 
the anterior and posterior ends of the embryo, which fuse to give 
rise to the primitive gut. This primitive gut structure subsequently 
undergoes significant patterning along the anterior–posterior 
axis and is delineated into three main areas: the foregut (esopha-
gus and stomach), midgut (small intestine), and hindgut (colon) 
(17). Anatomically, the foregut can further be divided into two 
portions, the anterior and posterior foregut, with the former giv-
ing rise to the esophagus, trachea, and lungs and the latter to the 
stomach, pancreas, and liver.
Of particular interest to the development of the foregut 
is the common origin of both the digestive and respiratory 
systems. Despite their differing function, the digestive and 
respiratory systems share a common embryonic origin, deriv-
ing from the developing anterior foregut. In mouse, between 
embryonic (E) days 9.5 and 11.5 (equivalent to weeks 4–6 in 
human gestation), a compartmentalization process takes place 
with the formation of the respiratory diverticulum (lung buds) 
from the ventral anterior foregut endoderm and the gradual 
separation of the ventral respiratory diverticulum from the 
dorsal anterior foregut by the esophagotracheal septum 
(Figure 1). This process ultimately results in the development 
of two independent and separate systems that will form the 
trachea and the esophagus (17).
The molecular processes that lead to compartmentalization, 
however, are not fully understood at present, and three main 
models have been proposed: the Outgrowth model (18, 19), the 
Watershed model (20), and the Septation model (21, 22).
The Septation model, which is currently the most accepted 
model of foregut development, suggests that lateral ridges of thick-
ening epithelium, along the dorsoventral midline, make contact 
across the lumen and fuse together, forming the esophagotracheal 
septum. Subsequently, this septum moves rostrally to separate 
the trachea and esophagus (21). Definitive affirmation of this 
model has been hampered by the paucity of available data on the 
development of the lateral ridge.
According to the Outgrowth model, the trachea sprouts from 
the primitive foregut and elongates forming the respiratory tube 
from the larynx to the lungs, while the foregut itself differentiates 
FiGURe 2 | Regional specification of the developing gut. Specification 
of the developing gut is determined initially by a concentration gradient of 
retinoic acid along the anterior–posterior axis.
FiGURe 1 | Compartmentalization of the foregut. At E9.5 in the mouse, 
the lung buds start to arise from the common foregut tube (dashed line; top). 
According to the Outgrowth model (bottom left), the trachea extends from 
the foregut tube at the level where lung buds develop (curved arrow). The 
Watershed model suggests that both developing trachea and esophagus 
elongate (arrows) from the diverging point (dashed line; middle). According to 
the Septation model (bottom right), a septum is formed from lateral ridges of 
mesenchyme, which moves up along the longitudinal axis of the common 
foregut tube separating the trachea and esophagus (arrow).
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into the esophagus (18, 19). By contrast, the Watershed model 
is based on the concept that a mesenchymal septum blocks 
elongation at the dorso/ventral midline of the foregut, while both 
trachea and esophagus elongate on the side (20). However, these 
two models are not supported by any scientific data. Both models 
postulate the presence of regions of increased proliferation, which 
has not yet been proven. For example, in the first scenario, a pro-
liferation “hot-spot” would be expected where the trachea buds 
from the foregut. Furthermore, these models assume that the 
common foregut does not elongate while the compartmentaliza-
tion takes place. Recent data however appear to suggest that the 
foregut tube actually decreases in length during the compartmen-
talization process (23). These findings taken together with genetic 
specification studies of the ventral foregut (24) lend weight to the 
Septation model.
MOLeCULAR SPeCiFiCATiON OF 
FOReGUT iN DeveLOPMeNT AND 
iMPLiCATiONS FOR OA/TOF
During gut development, many molecular pathways control 
and determine its regional specification. Of critical importance 
to the establishment of regional specification is the presence of 
retinoic acid (RA), a derivative of Vitamin A, along the anterior–
posterior axis in a concentration-dependent manner, whereby 
the pharynx is exposed to little RA and the colon to highest con-
centration of RA (Figure 2) (25). This RA gradient induces the 
expression of various transcription factors in different regions 
along the gut tube, thus specifying each region in turn. Despite 
the fact that fetal vitamin A deficiency in humans has not been 
associated with OA/TOF, it has been reported that mice deficient 
in RA signaling develop foregut compartmentalization defects 
(26–28). In particular, the absence of retinoic acid receptors, 
specifically in mice lacking either all RARA isoforms and RARB2 
or all RARB isoforms and RARA1, seems to block the foregut 
compartmentalization process, leading to the development of 
an undivided foregut with respiratory epithelium (28, 29). The 
role of RA in foregut development, along with its importance for 
pancreatic specification (30), has also been implicated in a mouse 
model that lacks RA-synthesizing retinaldehyde dehydrogenase 
2 (Aldh1a2), which results in embryonic death at around E10.5. 
These mice, if rescued with a short dose of RA, reach birth but 
develop similar foregut defects together with other cardiovascu-
lar anomalies (31). In terms of foregut development, Sox2 and 
Pdx1 expression appear to be vital signaling components for 
specification of the esophagus and of the stomach and pancreas, 
respectively (30, 32, 33).
In addition, dorsoventral specification, at the molecular 
level, in the foregut endoderm may help explain how the com-
partmentalization process of the trachea and esophagus occurs 
(Figure 3). Specifically, the dorsal foregut endoderm expressing 
Sox2 gives rise to the esophagus, while the ventral foregut endo-
derm expressing the transcription factor Nkx2.1 (34) forms the 
trachea. Both Sox2 and Nkx2.1 seem to be crucial factors involved 
in foregut separation as revealed in transgenic mouse models. 
Nkx2.1 null mice display incomplete foregut compartmentaliza-
tion, resulting in a condition similar to tracheal agenesis with the 
lungs directly connected with the foregut, ultimately resulting 
in respiratory failure (34). The exact role of Sox2 has been more 
difficult to determine as complete Sox2 loss-of-function results in 
embryonic death pre-gastrulation (35). However, investigations 
using hypomorphic and null alleles of Sox2 demonstrate that 
reduction in Sox2 levels results in an OA with TOF phenotype 
60% of the time (36). Moreover, this TOF phenotype displays res-
piratory characteristics, such as endodermal expression of Nkx2.1 
and the presence of cartilage (36). Therefore, it is clear that these 
two genes are necessary for organ specification of trachea and 
esophagus, but their specific role in the compartmentalization 
process is not proven (37).
Several signaling pathways determine the dorso/ventral pat-
terning of Sox2 and Nkx2.1. On the ventral side of the foregut, 
NKX2.1 protein expression is established by the production of 
FiGURe 3 | Dorsoventral patterning of the developing foregut 
endoderm. The dorsal (yellow) and ventral (blue) endoderm express Sox2 
and Nkx2.1, respectively. NOGGIN, produced by the surrounding 
mesenchyme (orange), regulates the expression of Sox2 in the dorsal foregut 
endoderm by directly activating Sox2 expression and indirectly inhibiting 
BMP4, which in turn inhibits Sox2. Ventrally, Wnt2/2b signaling activates the 
expression of Nkx2.1 in the ventral foregut endoderm, and WNT signaling 
also inhibits Nkx2.1 expression in the dorsal foregut endoderm. The mutual 
inhibition activity of Nkx2.1 and Sox2 create an expression gradient of these 
two genes, thereby allowing the separation of the two organs.
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BMP4 from the surrounding ventral mesenchyme, which acts 
through the BMP receptors BMPR1a, b in the ventral endoderm. 
If BMP4 is not produced in the mesenchyme or the endodermal 
receptors BMPR1a, b are absent, respiratory determination of the 
foregut will not proceed and tracheal agenesis may occur (38, 39). 
In this situation, Sox2 expression appears to expand along the 
ventral aspect of the foregut, suggesting that BMP signaling is 
important for repressing ventral Sox2 expression (37). Using a 
conditional knockout model of Bmpr1a, b, Domyan et al. dem-
onstrated that subsequent suppression of Sox2 can rescue Nkx2.1 
expression and the tracheal agenesis phenotype, suggesting that 
BMP signaling does not play a role in Nkx2.1 specification, but 
rather in Sox2 repression (38).
The BMP pathway is also important for dorsal foregut endo-
derm determination. More specifically, BMP ligands, produced 
in the ventral foregut mesenchyme, are counterbalanced by 
a BMP antagonist, NOGGIN, secreted by the dorsal foregut 
mesenchyme and the notochord (37). NOGGIN binds BMP4 to 
suppress BMP signaling in the dorsal endoderm (40), therefore 
allowing the expression of SOX2. Indeed, reduction in BMP 
antagonism causes OA/TOF as demonstrated by a 75% incidence 
of OA/TOF in Noggin null mutant mice (41). However, Fausett 
et al. have shown that Noggin is not critical for the dorso/ventral 
patterning of the foregut, which will express Sox2 and Nkx2.1 
in the absence of Noggin as demonstrated via investigation of 
Noggin null mice (42).
The initial endodermal patterning of the foregut is subse-
quently stabilized by interactions between the endoderm and 
visceral mesoderm adjacent to the gut tube. This interaction is 
initiated by sonic hedgehog (SHH), a member of the Hedgehog 
family of morphogens expressed by the endoderm along the 
length of the gut (43, 44), which subsequently upregulates various 
transcription factors that are regionally expressed in the visceral 
mesoderm. These include homeobox-containing transcription 
factors (Hox genes) that are crucial for the morphogenesis and 
cytodifferentiation that determines structure along the length of 
the GI tract (44).
Shh ligand acts via binding to its receptor and through GLI1, 
2, and 3 activating the transcription of target genes (45). For this 
reason, any deficiency in the downstream SHH pathway can cause 
disruption, mild to severe, in foregut development. For example, 
Gli2 null mice do not exhibit severe problems, with only mild 
lung defects and hypoplastic trachea and esophagus. By contrast, 
Gli2−/−;Gli3+/− mice present with a more severe lung phenotype 
including delayed or incomplete separation of the trachea and 
esophagus (46). Moreover, hedgehog signaling seems to be critical 
in foregut compartmentalization as demonstrated by the devel-
opment of abnormal esophageal and tracheal phenotypes in Shh  
null mice. In these mice, under-developed lung buds emerge 
directly from a single foregut tube connected to the stomach (43).
Another important molecular pathway involved in foregut 
specification is the WNT/β-catenin signaling pathway. WNT/β-
catenin signaling has been proven to be necessary and sufficient 
for respiratory cell fate of the ventral foregut, provided that Sox2 
expression is repressed by BMP signaling as discussed previously 
(38). WNTs are secreted glycoproteins that act trough β-catenin 
(Ctnnb1), a cytoplasmic protein that translocates to the nucleus 
and binds transcriptional repressors ultimately inducing transcrip-
tion of target genes (47). In terms of foregut development, WNT 
appears to be necessary for the ventral expression of Nkx2.1, with 
WNT2 and WNT2B, expressed in the ventral foregut mesenchyme, 
acting as important ligands involved in the compartmentalization 
process (48). Similar to loss of endodermal receptors BMPR1a, b 
in the foregut ventral endoderm, mesenchymal loss of WNT2 and 
WNT2b leads to disrupted endodermal expression of Nkx2.1 and 
results in disrupted tracheal formation (48). Similarly, conditional 
deletion of the WNT signaling mediator β-catenin in mouse 
foregut mesenchyme and epithelium impedes the compartmen-
talization of the foregut, resulting in tracheal agenesis (39, 49). 
Conversely, a significant expansion in Nkx2.1 expression through 
foregut endoderm, including the upper stomach epithelium, 
occurs if Ctnnb1 is constitutively activated (48) further confirm-
ing the importance of WNT/β-catenin signaling.
In addition to the advances in knowledge achieved using trans-
genic approaches in various animal models, pharmacological 
studies using Adriamycin administration (50, 51) have provided 
additional means to study and analyze disruption in foregut devel-
opment. Adriamycin, also called doxorubicin, is an anthracycline 
antibiotic and chemotherapeutic agent that, when injected in preg-
nant wild-type mice or rats before foregut compartmentalization, 
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causes phenotypes of VACTERL syndrome (21, 24). Doxorubicin 
acts by interfering with replication and therefore inhibits DNA 
and RNA synthesis, in this way affecting multiple tissues and 
organs. Furthermore, doxorubicin also affects the SHH–GLI 
receptor signaling pathway, giving rise to abnormalities during 
foregut development as previously described (52). Due to the 
clinical association of OA/TOF with syndromic malformations 
such as VACTERL, CHARGE (coloboma, heart defects, atresia 
of choanae, retardation of growth, and ear abnormalities), and Di 
George Syndrome, other genetic traits have been investigated for 
possible association of foregut malformation. T-box genes are a 
family of transcription factors richly expressed in tissues undergo-
ing active embryonic induction of organogenesis. TBX1 has been 
shown to be a major determinant in 22q11 deletion syndromes 
(22q11DS), including Di George syndrome; hence, the influ-
ence of TBX gene activity in the developing foregut has recently 
attracted significant interest. Using both wild-type mice and 
the aforementioned Adriamycin model, McLaughlin et al. have 
demonstrated a focal pattern of Tbx1 gene expression confined to 
the dorsal and ventral poles of the proximal wild-type esophagus. 
Altered Tbx1 foregut expression in Adriamycin treated animals 
in this study further suggests that Tbx1 may modulate normal 
esophageal development (53). Additional Tbx genes have been 
shown to play a role in foregut development. Tbx4 expression has 
been demonstrated in the lung buds and mesenchyme surround-
ing the trachea (54). Furthermore, Tbx4 has been shown to be 
specifically expressed in the visceral mesoderm of the developing 
lung in the chick model, and Tbx4 misexpression shown to induce 
disrupted formation of the tracheo-esophageal septum, ectopic 
budding of the lung and TOF, further confirming the crucial 
involvement of Tbx gene activity in foregut embryology.
DiSRUPTiON OF THe eNTeRiC  
NeRvOUS SYSTeM (eNS) iN OA
Esophageal dysmotility is a very common and well-recognized 
disorder in children suffering OA (55). Kirkpatrick et al. reported 
uncoordinated contractile waves in the distal esophagus in 14 
patients with OA (56), and others have associated GER with com-
plications due to the surgical procedure, such as excessive tension 
on the vagus nerve or overt injury to it at the site of the esopha-
geal anastomosis (57, 58). Although esophageal body motility 
dysfunction has been reported in patients following surgery, 
Lemoine et  al., using high-resolution esophageal manometry 
before surgical repair in two children with isolated TOF, demon-
strated that both had abnormal esophageal motility (hypomotility 
with distal contraction and complete aperistalsis) (59), suggesting 
that esophageal dysmotility is likely to be congenital.
This dysmotility is likely to be explained by loss, disruption, 
and/or dysfunction of the intrinsic innervation (ENS) of the 
esophagus. The ENS is derived principally from a population 
of vagal neural crest cells, which enter the foregut in humans at 
approximately week 4 (E9.5 in the mouse) (60) and migrate in a 
rostrocaudal fashion starting from the presumptive esophagus to 
colonize the entire gut by approximately week 7 (E13.5 in the mouse) 
(61, 62). To enable full gut colonization during embryogenesis, 
the neural crest cell population displays significant proliferative 
capacity. This proliferative capacity is tightly coordinated by Ret/
GDNF signaling (63), while SOX10 and endothelin 3 signaling 
have been shown to be critical in the maintenance of multilineage 
ENS progenitors (64). The ENS is organized into two concentric 
plexuses, the inner submucosal plexus is present in the submucosa 
and an outer myenteric plexus is present between the circular and 
longitudinal muscle layers along the length of the GI tract. In the 
normal esophagus, the ENS is largely present in the myenteric 
plexus and the submucosal plexus is absent or sparsely present. 
Nakazato et al. showed that the myenteric (Auerbach) plexus of 
infants with OA is deficient. Specifically, a lower amount of neural 
tissue was present in the distal esophagus compared to the proxi-
mal end of untreated OA patients and control patients (65). More 
recently, Boleken et al. suggested that the expression of neuronal 
markers, such as neurofilaments, specifically found in neuronal 
cells, and synaptophysin, a calcium-binding protein present in the 
presynaptic vesicles of neurons, were significantly reduced in the 
affected part of the esophagus while S100 expression, a marker of 
glial cells, was increased in the muscular layers and the myenteric 
plexus (66). Of interest, GDNF expression, an important neuro-
trophic factor for neural cells, was significantly reduced in these 
OA patients, suggesting a possible signaling deficiency, which 
could account for the observed intrinsic innervation deficits (66).
THe ROLe OF STeM CeLL THeRAPY  
AND TiSSUe eNGiNeeRiNG iN THe 
TReATMeNT OF OA/TOF
Despite advances in our understanding of the genetic determi-
nants of foregut development, this knowledge has not translated, 
as yet, to improved therapeutic interventions in the treatment of 
OA/TOF. Hence, alternative approaches using novel techniques 
such as gene and stem cell therapy in combination with advancing 
tissue engineering protocols may provide alternative routes for 
treatment of these difficult disorders following standard surgical 
intervention and pharmacological management. The current 
limitations of surgical approaches for the treatment of OA and 
TOF combined with the ongoing post-operative symptoms 
experienced by patients have provided the impetus to investigate 
potential cell-based therapies alone or combined with tissue engi-
neering as a means of replenishing missing or dysfunctional cell 
types or indeed absent sections of esophagus. Alternatively, they 
may provide a mechanism to treat ongoing foregut dysfunction, 
post-surgery, in less severe cases.
Arguably, the most promising approach lies in esophageal 
tissue engineering as a potential replacement of tissue segments. 
Tissue engineering approaches, using acellular scaffolds derived 
from animals and humans, or cell-seeded grafts, have recently 
been investigated (67). In particular, similar to a previous report 
for the trachea (68), decellularized esophageal scaffolds have been 
used with good results in both preclinical and clinical studies 
(69). Significant heterogeneity exists among studies, both with 
respect to the type of scaffold, and extent of surgery and species 
used, which partly explains the range of results reported. Badylak 
et al. laid sheets of small intestinal submucosa (SIS) onto the raw 
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internal surface of the esophagus following endoscopic submu-
cosal resection in five patients with superficial cancers (69). The 
scaffold promoted physiological remodeling and decreased the 
chance of stricture formation. Moreover, a commercially available 
extracellular matrix was able to promote full-thickness regenera-
tion of the esophagus with stratified squamous epithelium, a nor-
mal five-layer wall, and peristaltic motility with bolus transit (70). 
Decellularized esophageal tissue retains signals, both chemical and 
structural, which should promote appropriate migration and dif-
ferentiation of host cells (71–73), which may be unlikely to occur 
with scaffolds originating outside the esophagus, such as SIS. In an 
attempt to engineer a complex structure more closely resembling 
normal esophagus, Nakase et al. developed an elegant method for 
producing an esophageal construct. Oral keratinocytes and fibro-
blasts were cultured on human amniotic membrane and smooth 
muscle cells cultured on PGA. The two layers were rolled into a 
tube, implanted in the omentum, harvested at 3 weeks and used 
to replace a partial defect (74). Similarly, circumferential replace-
ment of the cervical esophagus was achieved using a tube-shaped 
tissue-engineered acellular substitute with autologous skeletal 
myoblasts covered by a human amniotic membrane seeded with 
autologous oral epithelial cells. Under the temporary cover of 
an esophageal endoprothesis, which was removed at 6 months, 
animals were able to reach nutritional autonomy and at sacrifice 
the tissue remodeled toward an esophageal phenotype (75).
While significant steps have been made in the ability to expand 
both epithelial and muscle cells for tissue engineering purposes 
(68), it will be essential to neo-innervate any potential engineered 
scaffold to allow for full restoration of function. To this end, major 
strides have been made in the last decade in the identification 
and isolation of enteric neural stem cells (ENSCs), which may 
not only provide an ideal candidate for neo-innervation of 
tissue-engineered scaffolds but may also provide a mechanism 
of restoring function in patients where ongoing dysfunction, fol-
lowing surgery, is found to be neuropathic. A number of studies 
have demonstrated that the human postnatal GI tract contains 
multipotent cells that upon transplantation can colonize the 
gut and differentiate into appropriate enteric neural phenotypes 
(76, 77). The proliferative capacity and multipotent nature of these 
neural crest derivatives has lead to investigation of the identifica-
tion and isolation of ENSCs. Recent investigations have sought to 
utilize such ENSC as a means of replacing lost or absent neurons 
in a number of GI disease models. Both mouse and human ENSC 
have been shown to integrate within mouse colonic tissues after 
transplantation (78–80). Previous studies have also demonstrated 
that ENSC can colonize aneural colonic tissues ex vivo (77). 
Importantly, both embryonic and postnatal mouse ENSC have 
been shown to integrate, differentiate into appropriate neuronal 
subtypes, and form functional neurons in vivo in recipient mouse 
models where the endogenous ENS persists (79). Furthermore, 
it has more recently been shown that human ENSC have the 
ability to colonize gut and integrate with the endogenous ENS 
in wild-type mouse colon, including functional integration of 
human fetal ENSC (78). These studies provide critical evidence 
that ENSC may provide a mechanism to restore function in vari-
ous gut tissues. Significantly, ENSCs have been identified in both 
human fetal (78) and postnatal tissues (77, 81), demonstrating 
the possibility of an autologous source of neural stem cells 
which could be harvested relatively easily via endoscopy, from 
other bowel regions, expanded, and then transplanted via tissue-
engineered scaffolds or autologous transplantation directly to the 
esophagus. A significant advantage of this approach would be the 
ability to circumvent immunological rejection of autologously 
transplanted cells. It may also be possible to perform heterologous 
transplantation of ENSC from matched donors; however, such 
an application is likely undesirable due to the possible require-
ment of lifelong immunosuppression. Future studies including 
preclinical evaluation of the ability of ENSC to provide functional 
rescue of foregut disorders and provide functional innervation 
within tissue-engineered specimens are required, prior to imple-
mentation of any clinical trials in human patients. One significant 
caveat regarding the use of ENSC is the potential limitation in 
their expansion characteristics. Transplantation studies, to date, 
have demonstrated relatively modest expansion and integration 
of ENSC within transplanted colonic tissues (79, 80), which may 
impact on their ability to restore function in large-scale human 
tissues. It remains possible that significant cell numbers will be 
required for the treatment of OA; therefore, studies of alternative 
cell sources are additionally required to determine the best cel-
lular source for esophageal neo-innervation.
To this end, there has been significant interest in the potential 
use of pluripotent stem cell (PSC) populations as a source of regen-
erative neural cells. Both embryonic stem (ES) cells and induced 
pluripotent stem (iPS) cells have the capacity to give rise to any 
cell of the body. Both mouse and human pluripotent stem cells 
(ES and iPS cells) can be differentiated into “ENS-like” cells (82) 
with capacity to proliferate limitlessly and therefore may provide 
an ideal cellular source for neo-innervation studies.
Of particular interest, recent studies have shown that ES and 
iPS cells can be manipulated in vitro to induce a neural crest-like 
phenotype (83–85). Recent work has demonstrated that human 
iPS-derived vagal-like neural crest cells can be combined with 
human pluripotent stem cell-derived intestinal organoids to form 
functional organoid units complete with neuronal reflexes (83). 
The ability to source autologous patient-derived iPS cells, which 
can be subsequently driven toward and ENS phenotype may revo-
lutionize treatments for enteric neuropathies allowing autologous 
cell therapy without lifelong immunosuppression. However, at 
present, limited data exist as to their integration and the ability 
of such cells to functionally rescue gut motility. Interestingly, 
Fattahi et al. recently suggested that human ES- and iPS-derived 
enteric neural crest could rescue a mouse model of Hirschsprung 
disease after in  vivo transplantation. Transplantation of these 
human-derived vagal neural crest cells to the colon of EDNRBs-l/s-l 
(SSL/LEJ) mice led to 100% survival; however, no mechanisms 
regarding the integration of these cells within the host neuromus-
culature, or the functional rescue achieved at the organ level, were 
presented (84). Therefore, further work is crucially required to 
establish the functional integration of PSC-derived neural crest 
cells after in vivo transplantation in a number of model systems.
While the potential expansion and manipulation of pluripotent 
stem cells provide an exciting proposition above that of ENSC, 
several issues remain to be addressed prior to their validation as a 
suitable treatment option. One critical issue regarding the potential 
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use of pluripotent stem cell sources is the potential introduction 
of residual pluripotent stem cells, which could be tumorigenic. 
Furthermore, studies are required to both consolidate and 
standardize protocols for the derivation of pure enteric neural 
crest cells and establish safety parameters for such pluripotent 
protocols, including genetic and epigenetic stability given that 
such derivations usually require significant culture periods. Such 
studies will allow for critical determination of the beneficial 
impacts of these cell replacement sources above that of autolo-
gously sourced ENSC.
CONCLUSiON AND FUTURe DiReCTiONS
The management of esophageal atresia remains challenging. This 
stems in part from a failure to understand the precise molecular 
mechanisms that underlie normal foregut development and the 
aberrations that lead to disease such as OA. As a result, therapies 
for OA are limited and designed to palliate rather than cure. Even 
when primary anastomosis is achieved in OA, the esophagus 
is often dysfunctional leading to major gastric and respiratory 
problems associated with poor quality of life. Treatments of 
complications related to OA are unsatisfactory and may require 
multiple surgeries. Some strides toward a better understanding 
of normal and abnormal development of the foregut have been 
made, but there is still a need for focused research in this area. 
This could lead to the development of innovative treatments. 
Regenerative medicine may have a role not only for filling the gap 
when primary anastomosis is not possible but also for ameliorat-
ing esophageal dysfunction. Alternatively, such dysfunction may 
be addressed more simply and directly utilizing the significant 
advances that have occurred in the field of ENSC biology. The 
transplantation of such cells may provide an adjunct to surgery 
to improve outcomes. Either way, the coming decade may well 
herald exciting prospects for the understanding of the origins of 
OA and the development of definitive therapies.
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